Determinants of Bacille Calmette-Guérin scarification in Danish children

Background: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for de...

Full description

Bibliographic Details
Main Authors: Trine Mølbæk Jensen, Signe Kjeldgaard Jensen, Nina Marie Birk, Andreas Rieckmann, Thomas Hoffmann, Christine Stabell Benn, Dorthe Lisbeth Jeppesen, Ole Pryds, Thomas Nørrelykke Nissen
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844020326001
id doaj-71768f5b5a764a31a36bcd7dd948a6f4
record_format Article
spelling doaj-71768f5b5a764a31a36bcd7dd948a6f42021-02-05T16:13:10ZengElsevierHeliyon2405-84402021-01-0171e05757Determinants of Bacille Calmette-Guérin scarification in Danish childrenTrine Mølbæk Jensen0Signe Kjeldgaard Jensen1Nina Marie Birk2Andreas Rieckmann3Thomas Hoffmann4Christine Stabell Benn5Dorthe Lisbeth Jeppesen6Ole Pryds7Thomas Nørrelykke Nissen8Department of Pediatrics, Copenhagen University Hospital, Hvidovre, Denmark; Corresponding author.Department of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkResearch Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Denmark; Section of Epidemiology, Department of Public Health, University of Copenhagen, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkResearch Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Denmark; Odense Patient Data Explorative Network (OPEN), Odense University Hospital/Department of Clinical Research, University of Southern Denmark, DK-5000 Odense, Denmark; Bandim Health Project, Guinea-BissauDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkDepartment of Pediatrics, Copenhagen University Hospital, Hvidovre, DenmarkBackground: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for developing a BCG-scar and for BCG scar size following neonatal BCG vaccination. Methods: At three Danish hospitals, newborns were randomized 1:1 to BCG vaccination or no BCG vaccination. The infants were invited for a clinical examination at the ages of 3 and 13 months. At 13 months, the scar site was inspected and scar size measured. We investigated three groups of determinants; external, parental, and individual-level determinants on relative scar prevalence and differences in median scar sizes. Results: Among 2118 BCG vaccinated infants, 2039 (96 %) were examined at 13 months; 1857 of these (91 %) had developed a BCG-scar. Compared with Copenhagen University Hospital, Hvidovre (85 %), Copenhagen University Hospital, Rigshospitalet had a scar prevalence of 95 % (adjusted Prevalence ratio (aPR) = 1.24 [CI 95 %: 1.18 to 1.30]); it was 93 % at Kolding Hospital (aPR 1.27 [CI 95 %: 1.19 to 1.35]). Increasing vaccine experience was positively associated with developing a scar and with scar size. Conclusion: Across multiple potential determinants of BCG scaring and size, logistical factors dominated. The results support that injection technique is an important determinant of developing a scar. Given the strong link between having a BCG scar and subsequent health, improved BCG vaccination technique could play a major role for child health.http://www.sciencedirect.com/science/article/pii/S2405844020326001BCG vaccineBCG scarNon-specific effectsHeterologous immunity
collection DOAJ
language English
format Article
sources DOAJ
author Trine Mølbæk Jensen
Signe Kjeldgaard Jensen
Nina Marie Birk
Andreas Rieckmann
Thomas Hoffmann
Christine Stabell Benn
Dorthe Lisbeth Jeppesen
Ole Pryds
Thomas Nørrelykke Nissen
spellingShingle Trine Mølbæk Jensen
Signe Kjeldgaard Jensen
Nina Marie Birk
Andreas Rieckmann
Thomas Hoffmann
Christine Stabell Benn
Dorthe Lisbeth Jeppesen
Ole Pryds
Thomas Nørrelykke Nissen
Determinants of Bacille Calmette-Guérin scarification in Danish children
Heliyon
BCG vaccine
BCG scar
Non-specific effects
Heterologous immunity
author_facet Trine Mølbæk Jensen
Signe Kjeldgaard Jensen
Nina Marie Birk
Andreas Rieckmann
Thomas Hoffmann
Christine Stabell Benn
Dorthe Lisbeth Jeppesen
Ole Pryds
Thomas Nørrelykke Nissen
author_sort Trine Mølbæk Jensen
title Determinants of Bacille Calmette-Guérin scarification in Danish children
title_short Determinants of Bacille Calmette-Guérin scarification in Danish children
title_full Determinants of Bacille Calmette-Guérin scarification in Danish children
title_fullStr Determinants of Bacille Calmette-Guérin scarification in Danish children
title_full_unstemmed Determinants of Bacille Calmette-Guérin scarification in Danish children
title_sort determinants of bacille calmette-guérin scarification in danish children
publisher Elsevier
series Heliyon
issn 2405-8440
publishDate 2021-01-01
description Background: Studies in low-income countries have shown that among Bacille Calmette-Guérin (BCG) vaccinated children, those who develop a BCG-scar have significantly better survival than those who do not develop a scar. In a Danish multicenter randomized clinical trial we assessed determinants for developing a BCG-scar and for BCG scar size following neonatal BCG vaccination. Methods: At three Danish hospitals, newborns were randomized 1:1 to BCG vaccination or no BCG vaccination. The infants were invited for a clinical examination at the ages of 3 and 13 months. At 13 months, the scar site was inspected and scar size measured. We investigated three groups of determinants; external, parental, and individual-level determinants on relative scar prevalence and differences in median scar sizes. Results: Among 2118 BCG vaccinated infants, 2039 (96 %) were examined at 13 months; 1857 of these (91 %) had developed a BCG-scar. Compared with Copenhagen University Hospital, Hvidovre (85 %), Copenhagen University Hospital, Rigshospitalet had a scar prevalence of 95 % (adjusted Prevalence ratio (aPR) = 1.24 [CI 95 %: 1.18 to 1.30]); it was 93 % at Kolding Hospital (aPR 1.27 [CI 95 %: 1.19 to 1.35]). Increasing vaccine experience was positively associated with developing a scar and with scar size. Conclusion: Across multiple potential determinants of BCG scaring and size, logistical factors dominated. The results support that injection technique is an important determinant of developing a scar. Given the strong link between having a BCG scar and subsequent health, improved BCG vaccination technique could play a major role for child health.
topic BCG vaccine
BCG scar
Non-specific effects
Heterologous immunity
url http://www.sciencedirect.com/science/article/pii/S2405844020326001
work_keys_str_mv AT trinemølbækjensen determinantsofbacillecalmetteguerinscarificationindanishchildren
AT signekjeldgaardjensen determinantsofbacillecalmetteguerinscarificationindanishchildren
AT ninamariebirk determinantsofbacillecalmetteguerinscarificationindanishchildren
AT andreasrieckmann determinantsofbacillecalmetteguerinscarificationindanishchildren
AT thomashoffmann determinantsofbacillecalmetteguerinscarificationindanishchildren
AT christinestabellbenn determinantsofbacillecalmetteguerinscarificationindanishchildren
AT dorthelisbethjeppesen determinantsofbacillecalmetteguerinscarificationindanishchildren
AT olepryds determinantsofbacillecalmetteguerinscarificationindanishchildren
AT thomasnørrelykkenissen determinantsofbacillecalmetteguerinscarificationindanishchildren
_version_ 1724283359382732800